Opexa Therapeutics Inc (NASDAQ:OPXA) was a notable mover during Tuesday’s trading session. The stock was higher by close to 4% on the back of relatively low volumes. The stock has been in a strong uptrend but has been unable to move above the psychological resistance level of $5.09 on repeated attempts, which is a bearish sign. The stock breached below its 200 day moving average during the trading session indicative of the strong selling interest. The index for relative strength has given a sell signal, which is a huge negative. Traders see the stock heading to levels of $3.42 in the near term.
Opexa Therapeutics Inc (NASDAQ:OPXA) announced that it was chosen by a panel of independent experts as one of the “Top Projects to Watch.” As per the reports, it’s the third consecutive year when Opexa has received this honor.
Opexa is one of the leading biopharmaceutical companies that’s known for developing world-class personalized immunotherapies for different autoimmune disorders, such as Neuromyelitis Optica (NMO) and multiple sclerosis (MS).
Insights of The Matter
It was a major recognition for the company. Post this announcement, company’s president Neil K. Warma, was asked to present the overview of Opexa at the prestigious Therapeutic Area Partnerships meeting. It was held at the Hilton Boston Back Bay between November 18-20.
According to Marc Wortman, E. Director, Therapeutic Area Partnerships, the selection procedure was very tough and strict. There’s no chance of any loophole in the selection procedure, which means all the selected companies are the best ones among those that applied to be considered for Top Projects to Watch. Some of the points that were paid heed at the time of selecting winners include market potential, unmet medical need, and diversity of indications, multi-level partnering opportunities, strong science and corporate stability.
The primary fact that prompted Therapeutic Area Partnerships to opt for such rigorous procedure was the willingness to select the best candidates in the market and offering them the exposure they deserved. It always wants to offer world-class exposure to all the potential partners, investors, and acquirers, so that they can grow to the heights they deserve.
Warma said that it was an honor to be selected as one among the best in the industry. It’s the evidence of the hard work and dedication shown by Opexa Therapeutics towards developing best products and making them available at a wide scale. The company will continue to work hard in the future to make sure that it can live up to everyone’s expectations.